Johnson & Johnson MedTech Unveils Unified Branding for Five Subsidiaries
Johnson & Johnson
Healthcare Product Manufacturers, Health Service Providers
Source: Siyu MedTech
On September 10, 2024, Johnson & Johnson stated that it is integrating its many medical technology brands under one banner to further streamline the company's brand presentation.
In the future, Ethicon, DePuy Synthes, Biosense Webster, Abiomed, and Cerenovus, all under the group, will operate under the name of Johnson & Johnson MedTech. Johnson & Johnson stated that this move will not bring any changes to its various product portfolios.
Johnson & Johnson has announced the integration of its medical technology brands Ethicon, DePuy Synthes, Biosense Webster, Abiomed, and Cerenovus under a unified brand, Johnson & Johnson MedTech.
This brand integration will not affect the medical technology products and solutions currently provided to customers by these brands. This change will begin to be reflected in social media channels and marketing materials in the coming weeks, and the updated brand and visual identity will not impact the Johnson & Johnson Medical Technologies product portfolio.
Johnson & Johnson aims to more clearly demonstrate its influence in the healthcare field through this integration initiative, thereby strengthening its competitiveness. At the same time, this move will also help streamline the company's overall brand image, making it easier for consumers and partners to recognize and understand the different businesses and products under Johnson & Johnson.
The announcement did not mention whether there would be any changes to Johnson & Johnson Vision (the division of Johnson & Johnson dedicated to ophthalmic operations), nor did it mention breast implant manufacturer Mentor and the acquired Shockwave Medical.
Tim Schmid, Chairman of Johnson & Johnson’s Global Medical Technology Business, said in a statement this week:
"Ethicon, DePuy Synthes, Biosense Webster, Abiomed, and CERENOVUS will be renamed as Johnson & Johnson Medical Technology Company, but we will continue to honor the heritage of these brands, maintaining their products, services, and collaborative approaches, making them one of the most trusted brands in the medical field."
Ethicon
Ethicon, a subsidiary of Johnson & Johnson, is dedicated to developing innovative products for laparoscopic and minimally invasive surgical procedures. Ethicon's products are widely used in various fields such as cardiovascular surgery, general surgery, breast surgery, plastic surgery, spinal surgery, wound closure, and ligation.
On May 29, 2024, Ethicon announced the launch of the first linear surgical stapler, Echelon, in the United States.
Johnson & Johnson Medical Technologies stated that this is the first linear surgical stapler to combine 3D stapling technology with Gripping Surface Technology (GST), designed to enhance safety, reduce surgical risks, and improve treatment outcomes.
DePuy Synthes
DePuy Synthes, a subsidiary of Johnson & Johnson, is one of the largest orthopedic companies in the world. It offers a comprehensive portfolio of orthopedic products, including solutions in joint reconstruction, trauma care, craniomaxillofacial, spinal surgery, and sports medicine.
DePuy Synthes' products are designed to help patients regain mobility, offering systems for knee, hip, and shoulder replacements, as well as spinal fixation devices and trauma products.
Innovative Product TriALTIS Spinal System
On October 9, 2023, DePuy Synthes announced that its TriALTIS™ Spinal System and navigation instruments had received FDA 510(k) clearance in the United States.
Biosense Webster
Biosense Webster, a subsidiary of Johnson & Johnson, specializes in the field of cardiac electrophysiology and is renowned for its innovative electrophysiological mapping and ablation technologies. The company launched the world's first 3D cardiac electrophysiological mapping system in 1995 and was acquired by Johnson & Johnson in 1996.
Biosense Webster's products and technologies are widely used in the diagnosis and treatment of arrhythmias, including but not limited to atrial fibrillation, supraventricular tachycardia, ventricular tachycardia, and other cardiac conditions.
Biosense Webster's main products include: 3D cardiac electrophysiology mapping systems, catheters for radiofrequency ablation and pulsed field ablation (PFA), diagnostic catheters, etc.
Biosense Webster is developing and promoting PFA technology, a new type of non-thermal ablation technology that treats arrhythmias by disrupting heart tissue with an electric field.
Abiomed
Abiomed is a medical technology company focused on the development and production of cardiac support devices, with its core product being the Impella series of heart pumps.
The Impella heart pump is a temporary solution used to support patients undergoing heart surgery or with heart failure, providing circulatory support and helping the heart maintain adequate blood flow.
Abiomed's products also include the Abiomed Breethe OXY-1 System, a cardiopulmonary support system with an integrated oxygen concentrator that provides patients with an independent oxygen source to support their mobility.
Cerenovus
A neurovascular business brand under Johnson & Johnson Medical Technologies, focusing on providing treatment solutions for hemorrhagic and ischemic strokes.
Cerenovus's product portfolio includes a variety of devices and instruments for neurointerventional procedures, such as catheters, stents, aspiration systems, etc., designed to help doctors diagnose and treat stroke more effectively.
On September 14, 2023, Johnson & Johnson announced that the company is about to undergo a brand renewal, making three adjustments:
Integrate its two major businesses, medical technology and pharmaceuticals, under the name of Johnson & Johnson.
The pharmaceutical business "Janssen Pharmaceuticals" will be renamed "Johnson & Johnson Innovative Medicine"; Johnson & Johnson Medical Technologies will remain unchanged.
Johnson & Johnson replaced its brand logo that had been used for 135 years, introduced a newly designed emblem, and highlighted the abbreviated brand logo "J&J" in application scenarios such as digital interfaces.
Johnson & Johnson (NYSE: JNJ), founded in 1886, is the world's most comprehensive healthcare enterprise with a wide range of business operations, covering three major fields: consumer goods, pharmaceuticals, and medical devices.
Headquartered in New Brunswick, New Jersey, USA, with more than 260 operating companies in 60 countries and regions worldwide, and over 140,000 employees globally.
On April 17, 2024, Johnson & Johnson announced its Q1 financial report for the fiscal year 2024, with total revenue of $21.383 billion (approximately RMB 154.789 billion), representing a year-over-year increase of 2.3%.
On May 31, 2024, Johnson & Johnson announced the completion of its acquisition of Shockwave Medical for $13.1 billion (approximately RMB 94.864 billion).
It is reported that Johnson & Johnson plans to appoint Michael Bodner, currently serving as the Global Head of Cardiac Recovery at Abiomed, to lead this business.
*Advertisement
▼More Book Recommendations▼
If you find the content rewarding, welcomeStar Marker、Like、Forward！
Your support is our greatest motivation
